Relmada’s Stock Soars 30.9% on 91% Phase 2 Response, Phase III Trials in Sight

Relmada Therapeutics Inc (NASDAQ: RLMD)

On August 29, 2025, Relmada Therapeutics Inc closed at $1.0142 per share, reflecting a 30.86% increase on a trading volume of 8,821,835. The clinical-stage biotechnology company, headquartered in Coral Gables, Florida, develops therapies for central nervous system and oncological disorders.

Corporate Structure

Relmada employs between 11 and 50 staff members, drawing on experience from various biopharmaceutical firms, including Johnson & Johnson, Eli Lilly, and Novartis. Its executive team includes:

• Sergio Traversa, CEO, who has over 25 years of experience in healthcare management and previously held leadership roles at Medeor Inc.
• Maged Shenouda, CFO, who has a background as an equity research analyst at UBS, JPMorgan, and Stifel, along with business development experience at AzurRx BioPharma.
• Charles Ence, Chief Accounting and Compliance Officer, previously served as controller and CFO at New Age Beverages Corp.

Biotechnology by Sangharsh Lohakare

Recent Developments

In late 2024, Relmada discontinued its Phase 3 program for REL-1017 in major depressive disorder and redirected its focus to strategic product acquisitions. During the American Urological Association meeting from April 26 to 29, 2025, the company provided updates on its lead oncology program, NDV-01, presenting six-month Phase 2 follow-up data indicating a 91% complete response rate in patients with high-grade non-muscle invasive bladder cancer. Preparations are in progress to initiate a Phase III registration trial in the first half of 2026.

On August 7, 2025, Relmada filed both an 8-K and a Form 10-Q. The 8-K reported corporate updates under Items 2.02, 7.01, and 9.01, while the 10-Q detailed quarterly financial metrics, including R&D spending and cash position (available on SEC.gov).

In an amendment to its Schedule 13G/A filed on August 14, 2025, Squadron Master Fund LP disclosed beneficial ownership of 2,914,495 shares (8.8% of the class). Squadron Capital Management LLC and William Blank reported ownership of 3,298,500 shares (9.9% of the class).

Financial and Strategic Analysis

Relmada’s market capitalization remains relatively modest, and the increase in share price on August 29 indicates investor interest in upcoming developments. The company is prioritizing:

1. Advancement of NDV-01 toward Phase III.
2. Progression of sepranolone, a GABAA-modulating steroid antagonist, into a planned Phase 2 study for Prader-Willi syndrome and other compulsive disorders in the first half of 2026.
3. Strategic product acquisitions to extend its pipeline while maintaining careful resource allocation.

Notably, major shareholders lack sole voting power, which may necessitate consensus among significant stakeholders for strategic decisions.

Market Position and Industry Context

Operating within specialty oncology and rare central nervous system disorders, Relmada targets areas with limited treatment options. Its NDV-01 intravesical formulation competes with established bladder cancer therapies, while sepranolone enters a market with unmet needs for behavioral and neuroendocrine conditions. The broader biotech sector faces regulatory scrutiny and financing challenges; Relmada's capacity to secure funding or collaborate with larger partners will influence its competitive position.

tl;dr

On August 29, RLMD shares rose 30.86% to $1.0142 on significant trading volume. The company filed important disclosures on August 7 (8-K and 10-Q) and amended its Schedule 13G/A on August 14, indicating significant investor holdings of approximately 10% each. Six-month Phase 2 data for NDV-01 reported a 91% complete response rate, with Phase III trials planned for the first half of 2026. Sepranolone is set to enter Phase 2 trials for Prader-Willi syndrome in early 2026. Relmada is focused on clinical milestones and strategic acquisitions to enhance its pipeline.